CRISPR Therapeutics AG (CRSP) Times Interest Earned (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Times Interest Earned of -$8.96 for Q1 2026, up 98.86% sequentially from -$789.61 in Q4 2025.
CRISPR Therapeutics AG (CRSP) Times Interest Earned (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Times Interest Earned for 12 years, with the latest figure at -$8.96 in Q1 2026.
- Quarterly Times Interest Earned changed N/A year-over-year to -$8.96 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.49 (up 80.7% YoY) and the FY2025 annual result came in at -$15.72, up 2.45% from the prior year.
- Times Interest Earned improved to -$8.96 in Q1 2026 per CRSP's latest filing, from -$789.61 in the prior quarter.
- Over five years, Times Interest Earned peaked at $0.6 in Q4 2023 and troughed at -$1245.8 in Q3 2025.
- A 5-year average of -$197.85 and a median of -$10.25 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2025: Times Interest Earned jumped 190.67% in 2023, then plunged 17076.65% in 2025.
- Over 5 years, Times Interest Earned stood at -$0.66 in 2022, then surged by 190.67% to $0.6 in 2023, then sank by 864.25% to -$4.6 in 2024, then slumped by 17076.65% to -$789.61 in 2025, then surged by 98.86% to -$8.96 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$8.96, -$789.61, and -$1245.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -8.50 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.50 |
| Mar 31, 2026 | -8.96 |
| Dec 31, 2025 | -789.61 |
| Sep 30, 2025 | -1,245.84 |
| Jun 30, 2025 | -482.79 |
| Dec 31, 2024 | -4.60 |
| Sep 30, 2024 | -478.83 |
| Jun 30, 2024 | -42.83 |
| Mar 31, 2024 | -49.54 |
| Dec 31, 2023 | 0.60 |
| Sep 30, 2023 | -18.74 |
| Jun 30, 2023 | -10.09 |
| Mar 31, 2023 | -6.08 |
| Dec 31, 2022 | -0.66 |
| Sep 30, 2022 | -8.25 |
| Jun 30, 2022 | -9.05 |
| Mar 31, 2022 | -10.41 |
| Dec 31, 2021 | -0.66 |
| Sep 30, 2021 | -134.78 |
| Jun 30, 2021 | 990.41 |